Xlife Sciences AG
SIX:XLS
Xlife Sciences AG
Research & Development
Xlife Sciences AG
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Xlife Sciences AG
SIX:XLS
|
Research & Development
-CHf15.6k
|
CAGR 3-Years
55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bachem Holding AG
SIX:BANB
|
Research & Development
-CHf10.2m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-17%
|
|
|
Siegfried Holding AG
SIX:SFZN
|
Research & Development
-CHf46.2m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Lonza Group AG
SIX:LONN
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Tecan Group AG
SIX:TECN
|
Research & Development
-CHf51.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
SKAN Group AG
SIX:SKAN
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Xlife Sciences AG
Glance View
Xlife Sciences AG focuses on the value development of performance promising technologies in life sciences. The company is headquartered in Zurich, Zuerich and currently employs 19 full-time employees. The company went IPO on 2019-09-30. The firm focuses on investing in technologies in the life science industry. The company supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. The firm offers its investors direct access to the further development of technologies at a very early stage. The firm cooperates with industrial partners and universities.
See Also
What is Xlife Sciences AG's Research & Development?
Research & Development
-15.6k
CHF
Based on the financial report for Dec 31, 2024, Xlife Sciences AG's Research & Development amounts to -15.6k CHF.
What is Xlife Sciences AG's Research & Development growth rate?
Research & Development CAGR 3Y
55%
Over the last year, the Research & Development growth was 94%. The average annual Research & Development growth rates for Xlife Sciences AG have been 55% over the past three years .
